Search Result
Results for "
mesenchymal
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N7702
-
|
Wnt
β-catenin
|
Metabolic Disease
|
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis .
|
-
-
- HY-151424
-
|
Proteasome
|
Cancer
|
Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin (VIM), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1 .
|
-
-
- HY-N7019
-
|
Others
|
Cancer
|
19-Hydroxybufalin is a bufadienolide, inhibits epithelial-mesenchymal transition and attenuates the migration and invasion of PC3 cells .
|
-
-
- HY-103038
-
ML327
4 Publications Verification
|
c-Myc
Autophagy
|
Cancer
|
ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
|
-
-
- HY-N7972
-
|
Others
|
Cancer
|
19-Oxocinobufotalin is capable of suppressing EMT (Epithelial-mesenchymal transition) and weakening the migratory and invasive potential of PC3 cells .
|
-
-
- HY-122965
-
|
FAK
Akt
|
Cancer
|
Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities .
|
-
-
- HY-152084
-
|
Others
|
Cancer
|
Anticancer agent 93 is a 4-Hydroxycoumarin derivative. Anticancer agent 93 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
|
-
-
- HY-N8917
-
|
Phosphatase
|
Metabolic Disease
|
(3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane is a homoisoflavonoid. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane increases the level of alkaline phosphatase (ALP) activity. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane promotes mesenchymal stem cells (MSCs) osteogenesis, but cannot enhance MSCs proliferation. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane can be used for osteoporosis research .
|
-
-
- HY-160053
-
|
PDGFR
|
Cancer
|
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
|
-
-
- HY-152085
-
|
Others
|
Cancer
|
Anticancer agent 94 is a 4-Hydroxycoumarin derivative. Anticancer agent 94 can inhibit invasion and migration of lung cancer cells by modulating expression of epithelial-mesenchymal transition (EMT) effectors .
|
-
-
- HY-P99589
-
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
-
- HY-N7215
-
|
β-catenin
Wnt
|
Cancer
|
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.
|
-
-
- HY-124757
-
|
Proteasome
|
Inflammation/Immunology
|
FiVe1 is a potent vimentin (VIM; the intermediate filament and mesenchymal marker) inhibitor . FiVe1 promotes VIM disorganization and phosphorylation during metaphase, leading to mitotic catastrophe, multinucleation, and the loss of stemness.?FiVe1 selectively and irreversibly inhibits the growth of multiple FOXC2-expressing breast cancer cell lines (HMLER cells (IC50:?267 nM); FOXC2-HMLER cells (IC50:?447 nM). FiVe1 inhibits the migration of mesenchymally transformed cells .
|
-
-
- HY-108438
-
|
Others
|
Neurological Disease
|
TCS 2210 (compound 1) is a neuronal differentiation inducer in mesenchymal stem cells (MSCs). TCS 2210 increases expression of the neuronal markers β-III tubulin and neuron-specific enolase (NSE) .
|
-
-
- HY-B1057
-
Fenazoxine hydrochloride
|
β-catenin
|
Neurological Disease
Cancer
|
Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
|
-
-
- HY-B1057S2
-
Fenazoxine-d3
|
β-catenin
|
Neurological Disease
|
Nefopam-d3 is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells[1][2].
|
-
-
- HY-141494
-
|
PPAR
|
Metabolic Disease
|
Pparδ agonist 5, an orally active PPARδ-selective agonist (EC50=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo .
|
-
-
- HY-N4019
-
|
TGF-β Receptor
|
Metabolic Disease
|
Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways .
|
-
-
- HY-139708
-
|
iGluR
|
Neurological Disease
|
NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
|
-
-
- HY-113042
-
|
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw .
|
-
-
- HY-162153
-
|
FGFR
|
Cancer
|
CYY292 is an FGFR1 inhibitor that specifically targets the FGFR1/AKT/Snail pathway in GBM cells. CYY292 dose-dependently inhibits cancer cell proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration in vitro .
|
-
-
- HY-133115
-
|
β-catenin
|
Neurological Disease
|
N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo .
|
-
-
- HY-106019C
-
R75251 dihydrochloride
|
Cytochrome P450
RAR/RXR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .
|
-
-
- HY-106019
-
R75251
|
Cytochrome P450
RAR/RXR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
|
-
-
- HY-106019A
-
R75251 hydrochloride
|
Cytochrome P450
RAR/RXR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties .
|
-
-
- HY-151904
-
|
TAM Receptor
FLT3
PDGFR
|
Cancer
|
AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .
|
-
-
- HY-156512
-
|
TGF-beta/Smad
|
Cancer
|
DT-6 is an effective TGF-β1 inhibitor. DT-6 inhibits M2 macrophage induced epithelial to mesenchymal transition and invasive migration of cancer cells. DT-6 can be used for cancer diseases research .
|
-
-
- HY-B1057S
-
Fenazoxine-d3 hydrochloride
|
β-catenin
|
Neurological Disease
|
Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
|
-
-
- HY-B1057S1
-
Fenazoxine-d4 hydrochloride
|
Isotope-Labeled Compounds
β-catenin
|
Neurological Disease
|
Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
|
-
-
- HY-147511
-
|
PPAR
|
Others
|
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC50, 4.34 μM) .
|
-
-
- HY-124478
-
Ethyl 2,5-dihydroxybenzoate
|
Phosphatase
|
Metabolic Disease
|
Ethyl gentisate (Ethyl 2,5-dihydroxybenzoate) is a dual modulator for cell differentiation, that enhances the osteogenic differentiation of human mesenchymal stem cells (hMSCs) and alkaline phosphatase activity, inhibits RANKL-activated osteoclastogenesis in RAW264.7 cells, and balances the bone remodeling process .
|
-
-
- HY-161400
-
|
TGF-β Receptor
|
Cancer
|
TGFβRII-IN-2 (Compound 3n) is an inhibitor for transforming growth factor-β type II receptor (TGFβRII) with IC50 of 2.4 μM, which blocks endothelial-to-mesenchymal transition and cell migration in different cancer cell lines without perturbing the microtubule network .
|
-
-
- HY-B0449
-
|
Bacterial
Antibiotic
|
Infection
|
Methacycline hydrochloride is a tetracycline antibiotic and can inhibits bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis .
|
-
-
- HY-153910
-
|
Others
|
Cancer
|
AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
|
-
-
- HY-N0336
-
Butylidenephthalide
|
Parasite
|
Infection
|
3-Butylidenephthalide (Butylidenephthalide) is a phthalic anhydride derivative identified in Ligusticum chuanxiong Hort, and has larvicidal activity (LC50 of 1.56 mg/g for Spodoptera litura larvae) .
|
-
-
- HY-B0166G
-
-
-
- HY-N0554
-
|
HIV Protease
|
Infection
Cancer
|
Escin IA is a triterpene saponin isolated from Aesculus hippocastanum, which inhibits HIV-1 protease with IC50 values of 35 μM. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of epithelial-mesenchymal transition process by down-regulating LOXL2 expression .
|
-
-
- HY-N10335
-
|
FAK
|
Inflammation/Immunology
Cancer
|
Harringtonolide is a potent RACK1 inhibitor (IC50=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .
|
-
-
- HY-W587701
-
|
Bacterial
Antibiotic
|
|
Methacycline is a tetracycline antibiotic that inhibits bacterial protein synthesis. Methacycline is a potent inhibitor of epithelial-to-mesenchymal transition (EMT). Methacycline blocks EMT in vitro and inhibits fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline is an antimicrobial agent with potential for use in pulmonary fibrosis research .
|
-
-
- HY-19867A
-
TG-0054 hydrobromide
|
CXCR
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization . Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction .
|
-
-
- HY-N0088
-
Acetovanillone
|
NADPH Oxidase
|
Metabolic Disease
Inflammation/Immunology
|
Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM . Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model . Apocynin can also be used for cancer research . Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass .
|
-
-
- HY-16268
-
KGN
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
|
-
-
- HY-137454
-
|
Wnt
β-catenin
|
Inflammation/Immunology
|
Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research .
|
-
-
- HY-102082
-
|
Others
|
Inflammation/Immunology
|
Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation .
|
-
-
- HY-128859
-
|
Cytochrome P450
|
Metabolic Disease
|
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively .
|
-
-
- HY-N6896
-
|
TGF-beta/Smad
|
Cancer
|
Isoviolanthin, a flavonoid glycoside, could markedly inhibit TGF-β1-mediated migration and invasion by deactivating epithelial-mesenchymal transition (EMT) via the TGF-β/Smad and PI3K/Akt/mTOR pathways in HCC cells. Isoviolanthin exhibits no cytotoxic effects on normal liver LO2 cells .
|
-
-
- HY-W014502
-
|
Aryl Hydrocarbon Receptor
Endogenous Metabolite
|
Cancer
|
D-kynurenine, a metabolite of D-tryptophan, can serve as the bioprecursor of kynurenic acid (KYNA) and 3-hydroxykynurenine. D-Kynurenine is an agonist for G protein-coupled receptor, GPR109B. D-Kynurenine is a substrate in a fluorometric assay of D-amino acid oxidase. D-kynurenine promotes epithelial-to-mesenchymal transition via activating aryl hydrocarbon receptor (AHR) .
|
-
-
- HY-12564
-
|
Aurora Kinase
Apoptosis
|
Cancer
|
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells .
|
-
-
- HY-151976
-
|
STAT
|
Inflammation/Immunology
|
STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .
|
-
-
- HY-B0449R
-
|
Bacterial
Antibiotic
|
Infection
|
Methacycline (hydrochloride) (Standard) is the analytical standard of Methacycline (hydrochloride). This product is intended for research and analytical applications. Methacycline hydrochloride is a tetracycline antibiotic and can inhibits bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis .
|
-
- HY-108628
-
SU16f
1 Publications Verification
|
PDGFR
|
Cancer
|
SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
|
-
- HY-18766
-
|
TGF-β Receptor
p38 MAPK
|
Cancer
|
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung .
|
-
- HY-138657
-
|
Phosphatase
|
Cancer
|
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model .
|
-
- HY-147722
-
|
Carbonic Anhydrase
|
Cancer
|
hCAIX-IN-8 (compound 7i) is a potent and selective hCAIX inhibitor with IC50s of 1.99, 0.024, 1.10 µM for CAII, CAIX, CAVA respectively. hCAIX-IN-8 shows anti-proliferation activity with low toxicity. hCAIX-IN-8 decreases the epithelial to mesenchymal transitions and induces apoptosis. hCAIX-IN-8 inhibits cell migration and colonization potential .
|
-
- HY-147768
-
|
PI3K
Akt
Microtubule/Tubulin
MMP
Apoptosis
|
Cancer
|
PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .
|
-
- HY-151428
-
|
Ferroptosis
Apoptosis
Bcl-2 Family
COX
|
Cancer
|
Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
|
-
- HY-151429
-
|
Apoptosis
Ferroptosis
Bcl-2 Family
COX
|
Cancer
|
Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
|
-
- HY-N9561
-
|
CDK
STAT
|
Cancer
|
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis .
|
-
- HY-144256
-
|
Others
|
Cancer
|
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties .
|
-
- HY-151802
-
|
TrxR
|
Cancer
|
CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective .
|
-
- HY-149894
-
|
Biochemical Assay Reagents
|
Cancer
|
MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .
|
-
- HY-N0554R
-
|
HIV Protease
|
Infection
Cancer
|
Escin IA (Standard) is the analytical standard of Escin IA. This product is intended for research and analytical applications. Escin IA is a triterpene saponin isolated from Aesculus hippocastanum, which inhibits HIV-1 protease with IC50 values of 35 μM. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of epithelial-mesenchymal transition process by down-regulating LOXL2 expression .
|
-
- HY-17444
-
|
PPAR
|
Metabolic Disease
Cancer
|
Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC50s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ. Tesaglitazar induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats .
|
-
- HY-E70299
-
ST3GAL5
|
TGF-beta/Smad
|
Cancer
|
ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is a glycosphingolipid (GSL) biosynthetic enzyme that can inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 can be used in cancer research .
|
-
- HY-161398
-
|
TGF-β Receptor
TGF-beta/Smad
|
Cancer
|
TGFβRII-IN-3 (Compound 2r) is a selective inhibitor of the TGFβ type II receptor (TGFβ RII) (IC50 = 4.1 μM). TGFβRII-IN-3 inhibits TGFβ signaling by promoting the proteolytic degradation of TGFβ RII. TGFβRII-IN-3 can block endothelial-to-mesenchymal transition and cell migration. TGFβRII-IN-3 can be used in cancer research .
|
-
- HY-N0088R
-
|
NADPH Oxidase
|
Metabolic Disease
Inflammation/Immunology
|
Apocynin (Standard) is the analytical standard of Apocynin. This product is intended for research and analytical applications. Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM . Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model . Apocynin can also be used for cancer research . Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass .
|
-
- HY-124745
-
|
MAP4K
Wnt
Apoptosis
|
Cancer
|
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .
|
-
- HY-W014502R
-
|
Aryl Hydrocarbon Receptor
Endogenous Metabolite
|
Cancer
|
D-Kynurenine (Standard) is the analytical standard of D-Kynurenine. This product is intended for research and analytical applications. D-kynurenine, a metabolite of D-tryptophan, can serve as the bioprecursor of kynurenic acid (KYNA) and 3-hydroxykynurenine. D-Kynurenine is an agonist for G protein-coupled receptor, GPR109B. D-Kynurenine is a substrate in a fluorometric assay of D-amino acid oxidase. D-kynurenine promotes epithelial-to-mesenchymal transition via activating aryl hydrocarbon receptor (AHR) .
|
-
- HY-N6896R
-
|
TGF-beta/Smad
|
Cancer
|
Isoviolanthin (Standard) is the analytical standard of Isoviolanthin. This product is intended for research and analytical applications. Isoviolanthin, a flavonoid glycoside, could markedly inhibit TGF-β1-mediated migration and invasion by deactivating epithelial-mesenchymal transition (EMT) via the TGF-β/Smad and PI3K/Akt/mTOR pathways in HCC cells. Isoviolanthin exhibits no cytotoxic effects on normal liver LO2 cells .
|
-
- HY-162904
-
|
Mitochondrial Metabolism
Others
|
Cardiovascular Disease
|
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
|
-
- HY-150596
-
|
Apoptosis
Bcl-2 Family
JNK
|
Cancer
|
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
|
-
- HY-169332
-
|
Piezo Channel
ERK
|
Metabolic Disease
|
Piezo1 agonist 1-d2 (Compound 12a) is an agonist for Piezo1 with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates the Ca 2+-related ERK signaling pathway, and thus promotes the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Piezo1 agonist 1-d2 ameliorates disuse osteoporosis in the hindlimb-unloading (HU) rat model .
|
-
- HY-108692
-
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .
|
-
- HY-108692R
-
|
Apoptosis
Endogenous Metabolite
|
Cancer
|
Enterolactone (Standard) is the analytical standard of Enterolactone. This product is intended for research and analytical applications. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .
|
-
- HY-123931
-
ZLDI-8
1 Publications Verification
|
Notch
Phosphatase
Apoptosis
|
Cancer
|
ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM .
|
-
- HY-10071
-
Y-27632
Maximum Cited Publications
283 Publications Verification
|
Organoid
ROCK
Apoptosis
|
Cancer
|
Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
|
-
- HY-10071A
-
|
Organoid
ROCK
Apoptosis
|
Cancer
|
Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
|
-
- HY-113790
-
|
Others
|
Others
|
ISX-1 is an isoxazole. ISX-1 has anti-adipogenic and pro-osteogenic activities. ISX-1 can be used for the research of osteopenia and osteoporosis .
|
-
- HY-W025074
-
|
Sirtuin
Histone Methyltransferase
|
Cancer
|
BML-278 is a SIRT1 activator (EC150: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts .
|
-
- HY-N7210
-
|
Apoptosis
|
Cancer
|
Kahweol acetate, a bioactive compound found in coffee, has been identified for its potent anti-cancer properties, particularly in inhibiting the proliferation and migration of prostate cancer cells. Alongside cafestol, it shows dose-dependent effects in suppressing tumor growth and metastasis in both in vitro and in vivo studies. Mechanistically, kahweol acetate and cafestol induce apoptosis, inhibit epithelial-mesenchymal transition, and reduce androgen receptor activity, especially in androgen receptor-positive cells. They also downregulate chemokine receptors CCR2 and CCR5, crucial for cancer progression, without altering their ligand levels. These findings suggest that kahweol acetate, in combination with cafestol, may serve as promising therapeutic agents against prostate cancer .
|
-
- HY-P4322
-
|
ERK
Akt
|
Neurological Disease
Cancer
|
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .
|
-
- HY-W010713
-
Fimaporfin free base
|
Others
|
Cancer
|
Meso-tetraphenylchlorin (TPCS2a) is a photosensitizer with poor water solubility, which limits its use in the blood circulation. However, TPCS2a@NPs nanoparticles can be prepared based on polylactic-co-polyethylene glycol acid (PLGA) polymer core loaded with TPCS2. Such nanoparticles can be coated with mesenchymal stem cell-derived plasma membranes (mMSCs) to form mMSC-TPCS2a@NPs, which prolongs blood circulation time and improves tumor targeting ability. Compared with uncoated TPCS2a@NPs, mMSC-TPCS2a@NPs can reduce macrophage uptake by 54% to 70% under different conditions. Both nanoparticle forms are effectively accumulated in MCF7 and MDA-MB-231 breast cancer cells, while uptake in normal breast epithelial cells MCF10A is significantly lower .
|
-
- HY-12317
-
|
Smo
Hedgehog
|
Cancer
|
GSA-10 is a potent smooth (Smo) receptor agonist. GSA-10 is a potent osteogenic molecule. GSA-10 can mediate Hedgehog (Hh) signaling. GSA-10 can be used in regenerative medicine for cancer disease and in the study of fat development .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-B0166G
-
L-Ascorbate (GMP); Vitamin C (GMP)
|
Fluorescent Dye
|
L-Ascorbic acid (L-Ascorbate) (GMP) is L-Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Cav 3.2 channels .
|
Cat. No. |
Product Name |
Type |
-
- HY-B0166G
-
L-Ascorbate (GMP); Vitamin C (GMP)
|
Biochemical Assay Reagents
|
L-Ascorbic acid (L-Ascorbate) (GMP) is L-Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Cav 3.2 channels .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2632A
-
|
Peptides
|
Neurological Disease
|
RAD16-I hydrochloride, a soft nanofibrous self-assembling peptide, is a suitable microenvironment for human mesenchymal stem cells’ (hMSC) proliferation and differentiation into chondrocytes . RAD16-I is a well-studied ionic complementary peptide was used as a model to check potential amyloid-like staining properties of SAPNFs .
|
-
- HY-P0306
-
Heparin Binding Peptide
|
Peptides
|
Cardiovascular Disease
|
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
|
-
- HY-P4322
-
|
ERK
Akt
|
Neurological Disease
Cancer
|
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .
|
-
- HY-P3413
-
-
- HY-P5457
-
|
Peptides
|
Others
|
BMP-2 Epitope (73-92) is a biological active peptide. (This is amino acids 73 to 92 fragment of bone morphogenetic protein (BMP) knuckle epitope. It is a member of transforming growth factor beta (TGF-b). This peptide fragment is able to raise alkaline phosphate activity in murine multipotent mesenchymal cells.)
|
-
- HY-P2632
-
|
Peptides
|
Neurological Disease
|
RAD16-I, a soft nanofibrous self-assembling peptide, is a suitable microenvironment for human mesenchymal stem cells’ (hMSC) proliferation and differentiation into chondrocytes . RAD16-I is a well-studied ionic complementary peptide was used as a model to check potential amyloid-like staining properties of SAPNFs .
|
-
- HY-P0306A
-
Heparin Binding Peptide TFA
|
Peptides
|
Cardiovascular Disease
|
Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
|
-
- HY-P5291
-
Caerulein precursor fragment
|
Peptides
|
Metabolic Disease
|
CPF-7 (Caerulein precursor fragment) is an insulin-releasing peptide that stimulates the release of insulin. CPF-7 can induce epithelial-mesenchymal transition by upregulating Snai1 expression in PANC-1 ductal cells. CPF-7 also induces exocrine plasticity by upregulating Ngn3 expression. CPF-7 can be used in the research of type 2 diabetes .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99589
-
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N7702
-
-
-
- HY-N7019
-
-
-
- HY-N7972
-
-
-
- HY-122965
-
-
-
- HY-N4019
-
-
-
- HY-113042
-
-
-
- HY-N0336
-
-
-
- HY-N0554
-
-
-
- HY-N8917
-
-
-
- HY-N7215
-
-
-
- HY-N10335
-
-
-
- HY-N0088
-
-
-
- HY-102082
-
-
-
- HY-N6896
-
-
-
- HY-W014502
-
-
-
- HY-N9561
-
-
-
- HY-N0554R
-
-
-
- HY-N0088R
-
-
-
- HY-W014502R
-
|
Structural Classification
Ketones, Aldehydes, Acids
Endogenous metabolite
|
Aryl Hydrocarbon Receptor
Endogenous Metabolite
|
D-Kynurenine (Standard) is the analytical standard of D-Kynurenine. This product is intended for research and analytical applications. D-kynurenine, a metabolite of D-tryptophan, can serve as the bioprecursor of kynurenic acid (KYNA) and 3-hydroxykynurenine. D-Kynurenine is an agonist for G protein-coupled receptor, GPR109B. D-Kynurenine is a substrate in a fluorometric assay of D-amino acid oxidase. D-kynurenine promotes epithelial-to-mesenchymal transition via activating aryl hydrocarbon receptor (AHR) .
|
-
-
- HY-N6896R
-
-
-
- HY-108692
-
-
-
- HY-108692R
-
-
-
- HY-N7210
-
|
Structural Classification
Natural Products
Source classification
Rubiaceae
Plants
Coffea arabica L.
|
Apoptosis
|
Kahweol acetate, a bioactive compound found in coffee, has been identified for its potent anti-cancer properties, particularly in inhibiting the proliferation and migration of prostate cancer cells. Alongside cafestol, it shows dose-dependent effects in suppressing tumor growth and metastasis in both in vitro and in vivo studies. Mechanistically, kahweol acetate and cafestol induce apoptosis, inhibit epithelial-mesenchymal transition, and reduce androgen receptor activity, especially in androgen receptor-positive cells. They also downregulate chemokine receptors CCR2 and CCR5, crucial for cancer progression, without altering their ligand levels. These findings suggest that kahweol acetate, in combination with cafestol, may serve as promising therapeutic agents against prostate cancer .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1057S
-
|
Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
|
-
-
- HY-B1057S2
-
|
Nefopam-d3 is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells[1][2].
|
-
-
- HY-B1057S1
-
|
Nefopam-d4 (hydrochloride) is deuterium labeled Nefopam (hydrochloride). Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
|
-
-
- HY-169332
-
|
Piezo1 agonist 1-d2 (Compound 12a) is an agonist for Piezo1 with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates the Ca 2+-related ERK signaling pathway, and thus promotes the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Piezo1 agonist 1-d2 ameliorates disuse osteoporosis in the hindlimb-unloading (HU) rat model .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-160053
-
|
|
Aptamers
|
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: